- Home
- NEGG vs ADCT Comparison
NEGG vs ADCT Comparison
Compare NEGG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ADCT
- Stock Information
- Founded
- NEGG 2001
- ADCT 2011
- Country
- NEGG United States
- ADCT Switzerland
- Employees
- NEGG N/A
- ADCT N/A
- Industry
- NEGG Other Specialty Stores
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ADCT Health Care
- Exchange
- NEGG Nasdaq
- ADCT Nasdaq
- Market Cap
- NEGG 293.6M
- ADCT 224.3M
- IPO Year
- NEGG 2010
- ADCT 2020
- Fundamental
- Price
- NEGG $0.62
- ADCT $2.97
- Analyst Decision
- NEGG
- ADCT Strong Buy
- Analyst Count
- NEGG 0
- ADCT 5
- Target Price
- NEGG N/A
- ADCT $7.33
- AVG Volume (30 Days)
- NEGG 678.3K
- ADCT 897.3K
- Earning Date
- NEGG 12-17-2024
- ADCT 11-07-2024
- Dividend Yield
- NEGG N/A
- ADCT N/A
- EPS Growth
- NEGG N/A
- ADCT N/A
- EPS
- NEGG N/A
- ADCT N/A
- Revenue
- NEGG $1,391,833,000.00
- ADCT $70,717,000.00
- Revenue This Year
- NEGG $6.01
- ADCT $6.38
- Revenue Next Year
- NEGG N/A
- ADCT $11.73
- P/E Ratio
- NEGG N/A
- ADCT N/A
- Revenue Growth
- NEGG N/A
- ADCT N/A
- 52 Week Low
- NEGG $0.55
- ADCT $0.94
- 52 Week High
- NEGG $1.45
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- NEGG 51.19
- ADCT 41.63
- Support Level
- NEGG $0.62
- ADCT $1.80
- Resistance Level
- NEGG $0.64
- ADCT $2.38
- Average True Range (ATR)
- NEGG 0.04
- ADCT 0.20
- MACD
- NEGG 0.00
- ADCT 0.00
- Stochastic Oscillator
- NEGG 76.67
- ADCT 52.27
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.